Clinical trial of rituximab in interstitial lung disease secondary to systemic sclerosis

Not Applicable

• Conditions: Interstitial lung disease secondary to systemic sclerosis

• Registration Number: JPRN-UMIN000007702
• Lead Sponsor: Department of Dermatology, The University of Tokyo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-04-24
• Study Completion: 2021-10-21
• Last Update Posted: 20 November 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1)during treatment with equal drug 2)previous history of anaphylactic reactions to this drug 3)significant infection 4)significant liver damage 5)significant renal damage 6)less than or equal to 60% of %VC or 40% of %DLco 7)previous history of significant infection 8)pregnancy 9)breast-feeding 10)participating in other clinical trial within three months before the beginning of this trial 11)judged inappropriate for this study by the physicians

Study & Design

• Study Type: Interventional
• Study Design: Not specified